Some childhood experiences stay with us, quietly shaping how we feel as adults. For those raised in families with ...

Huntington’s disease doesn’t just damage the brain, it also breaks down muscles and fat, and disrupts nutrition early on. New work suggests there’s a hidden physical decline in early HD, so monitoring ...

Time-restricted eating (TRE) is a form of intermittent fasting. Instead of focusing on how much you eat, TRE focuses on when you eat. A typical schedule might allow meals only between 12 PM and 8 PM ...

July’s HD research roundup: Brain scans, gene editing, glial cells, and even smartphones reveal new ways to track and treat Huntington’s. From sleep to cell power, science is zooming in and bringing ...

A 12-year study reveals how disrupted sleep may predict Huntington’s disease onset, could link to changes in thinking and ...

Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this ...

Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an ...

Researchers have updated the system that classifies Huntington’s disease progression. Tracking progression in 4 stages will make clinical trial screening and data interpretation easier and faster, and ...

People who develop Huntington’s disease (HD) are born with the genetic change that causes the disease. So why does it take decades, usually around 40 to 50 years, for the symptoms of the disease to ...

Research led by Dr. Peg Nopoulos from the University of Iowa used the Enroll-HD database to answer a key question: “How does beta-blocker use influence motor-diagnosis onset and progression rates in ...

Catch up on all of the latest updates from day 1 of the 2021 CHDI Huntington’s disease therapeutics conference #HDTC2021 including presentations from Wave, Roche and Triplet.

The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.